Autopsy report · NCT03773510

Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin

“Not approved by the coordinating Ethical Committee”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Italian Sarcoma Group

Sponsor type

University, hospital or other

Conditions

Leiomyosarcoma; Liposarcoma; Synovial Sarcoma

Interventions

Trabectedin discontinuation; Trabectedin continuation

Participants

0

Sites

15

Countries

Italy

Trials that died the same way

• Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
  “No approval from ethical committee” (84% match in meaning)
• Identification of Post-Traumatic Stress Disorder in Adult Patients With Substance Use Disorders
  “Refusal by the Ethics Committee” (69% match in meaning)
• The Effect of ACT and Float REST on Burnout Syndrome.
  “Ethics Committee concerns.” (67% match in meaning)
• Sub-Cutaneous Insulin in Hyperglycaemic Emergencies
  “Ethics approval denied” (64% match in meaning)
• Changes in Ventilation Inhomogeneity and Respiratory Function Following Elective Caesarean Section Under Regional Anaesthesia
  “Ethical approval not obtained yet as questioning the danger of providing 100% oxygen to parturients.” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.